WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 555598

CAS#: 1800405-30-4

Description: KL1333 is an orally available, small organic molecule that reacts with NAD(P)H:quinone oxidoreductase 1 (NQO1) as a substrate, resulting in increases in intracellular NAD+ levels via NADH oxidation. KL-1333 Improves Energy Metabolism and Mitochondrial Dysfunction in MELAS Fibroblasts.

Price and Availability

Size Price Shipping out time Quantity
200mg USD 2250 2 Weeks
500mg USD 3650 2 Weeks
1g USD 4650 2 Weeks
2g USD 7950 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-19. Prices are subject to change without notice.

KL-1333, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received..

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 555598
Name: KL-1333
CAS#: 1800405-30-4
Chemical Formula: C14H12N2O2
Exact Mass: 240.0899
Molecular Weight: 240.262
Elemental Analysis: C, 69.99; H, 5.03; N, 11.66; O, 13.32

Synonym: KL-1333; KL 1333; KL1333;

IUPAC/Chemical Name: 2-(1-Methylethyl)-3H-naphth(1,2-d)imidazole-4,5-dione


InChi Code: InChI=1S/C14H12N2O2/c1-7(2)14-15-10-8-5-3-4-6-9(8)12(17)13(18)11(10)16-14/h3-7H,1-2H3,(H,15,16)

SMILES Code: O=C(C1=C2N=C(C(C)C)N1)C(C3=C2C=CC=C3)=O

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Additional Information

Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), one of the most common maternally inherited mitochondrial diseases, is caused by mitochondrial DNA mutations that lead to mitochondrial dysfunction. Several treatment options exist, including supplementation with CoQ10, vitamins, and nutrients, but no treatment with proven efficacy is currently available.